<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379418</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00021864</org_study_id>
    <nct_id>NCT00379418</nct_id>
  </id_info>
  <brief_title>Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients</brief_title>
  <acronym>AIR</acronym>
  <official_title>Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIR STUDY

      TITLE: Anti-Ischemic effects of Abciximab(Reopro)

      PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small
      stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable
      statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor).

      INTERVENTION: Heparin vs. heparin + abciximab during PCI

      PURPOSE: Measure the effects of abciximab on special healing blood stem cells
      (EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on
      microvascular blood flow.

      PATIENT ASSESSMENT:

        1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28.

        2. Measurement of blood flow in selected suitable patients

        3. 10 minute questionnaire before discharge and on visit on day 28.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">220</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <other_name>Reopro</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with coronary artery disease undergoing left heart catheterization
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have either:

               -  clinical history of anginal symptoms or positive stress test or

               -  in stent restenosis

          2. Have an angiographic &gt;70% coronary artery stenosis that will be treated with coronary
             angioplasty or stenting procedure

          3. For at least four weeks prior to the procedure have been on, no Hmgcoa- reductase
             inhibitor or a stable statin dose

          4. negative pregnancy test

          5. are able to give informed consent

        Exclusion Criteria:

          1. Coronary intervention within four weeks prior to enrollment.

          2. Treatment with abciximab antagonist within four weeks.

          3. treatment with thrombolytic therapy within 48 hours

          4. MI within 2 months.

          5. recent infections

          6. general anesthesia within 3 months.

          7. renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arshed A Quyyumi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>EUH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2006</study_first_submitted>
  <study_first_submitted_qc>September 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <last_update_submitted>September 11, 2013</last_update_submitted>
  <last_update_submitted_qc>September 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Kreton Mavromatis, MD, FACC</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

